2. Search Result
Search Result
Results for "

monoacylglycerol lipase (MAGL)

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

3

Recombinant Proteins

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136562
    N-Arachidonyl maleimide

    		MAGL Metabolic Disease
    N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC50 value of 140 nM .
    N-Arachidonyl maleimide
  • HY-12332
    JW 642
    2 Publications Verification

    		 MAGL Neurological Disease
    JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.
    JW 642
  • HY-119283
    CAY10499
    1 Publications Verification

    MAGL-IN-5

    		 MAGL FAAH SARS-CoV Influenza Virus Infection Metabolic Disease Inflammation/Immunology
    CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC50 values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities .
    CAY10499
  • HY-117632
    Elcubragistat
    1 Publications Verification

    ABX-1431

    		 MAGL Neurological Disease
    Elcubragistat (ABX-1431) is a highly potent, selective, and orally available, CNS-penetrant monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 14 nM.
    Elcubragistat
  • HY-132310
    MAGL-IN-4

    		MAGL Neurological Disease
    MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .
    MAGL-IN-4
  • HY-157041
    MAGL-IN-10

    		MAGL Cancer
    MAGL-IN-10 is areversible monoacylglycerol lipase (MAGL) inhibitor with very good ADME properties and low in vivo toxicity.MAGL-IN-10 can be used for the research ofcancer, neurological disorders and inflammatory pathologies .
    MAGL-IN-10
  • HY-168032
    MAGL-IN-18

    		MAGL Inflammation/Immunology
    MAGL-IN-18 (compound 118) is a potent Monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 0.03 nM .
    MAGL-IN-18
  • HY-168459
    MAGL-IN-21

    		MAGL Neurological Disease
    MAGL-IN-21 (Compound (S)-6) is a selective inhibitor for monoacylglycerol lipase (MAGL) with an IC50 of 1.59 nM .
    MAGL-IN-21
  • HY-157038
    MAGL-IN-8

    		MAGL Inflammation/Immunology
    MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC50 of 2.5 ± 0.4 nM for hMAGL .
    MAGL-IN-8
  • HY-146342
    FAAH/MAGL-IN-3

    		FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH/MAGL-IN-3
  • HY-15250
    JZL195
    4 Publications Verification

    		 FAAH MAGL Autophagy Neurological Disease
    JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively .
    JZL195
  • HY-169239
    MAGL-IN-20

    		MAGL Cancer
    MAGL-IN-20 (compound ±34) is a reversible monoacylglycerol lipase (MAGL) inhibitor. MAGL-IN-20 exhibits appreciable antiproliferative activities against several cancer cells, including H460, HT29, CT-26, Huh7 and HCCLM-3. .
    MAGL-IN-20
  • HY-124576
    ABD-1970

    		MAGL Neurological Disease
    ABD-1970 is a selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 15 nM and 29 nM for human and mouse MAGL, respectively. ABD-1970 shows selectivity for MGLL over other members of the serine hydrolase class. ABD-1970 has the potential for the study of neurological disorders .
    ABD-1970
  • HY-108613
    JJKK 048
    1 Publications Verification

    		 MAGL Neurological Disease Cancer
    JJKK 048 is a highly selective and potent monoacylglycerol lipase (MAGL) inhibitor with IC50 values of 214 pM, 275 pM and 363 pM for human, rat, and mouse MAGL. JJKK 048 displays low cross-reactivity with other endocannabinoid targets. JJKK 048 can be used in the research of diseases such as cancer, neurodegenerative diseases, and pain .
    JJKK 048
  • HY-121476
    Arachidonoyl Serinol

    		MAGL Neurological Disease
    Arachidonoyl Serinol, an endogenous cannabimimetic metabolite, is an inhibitor of monoacylglycerol lipase (MAGL). Arachidonoyl Serinol inhibits the hydrolysis of [ 3H]2-oleoylglycerol and [ 3H]anandamide with IC50s of ～70 μM .
    Arachidonoyl Serinol
  • HY-120560
    OMDM169

    		MAGL Neurological Disease
    OMDM169 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor with activity to increase 2-AG levels. OMDM169 exerts analgesic activity through indirect activation of cannabinoid receptors. The effective concentration of OMDM169 is 0.13 μM .
    OMDM169
  • HY-133130
    JNJ-42226314

    		MAGL Neurological Disease
    JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-117474
    MJN110
    3 Publications Verification

    		 MAGL Neurological Disease
    MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity .
    MJN110
  • HY-139182
    MAGL-IN-3

    		Endogenous Metabolite Metabolic Disease
    CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.
    MAGL-IN-3
  • HY-116141
    7-Hydroxycoumarinyl arachidonate

    7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate

    		 Phospholipase MAGL Others
    7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer .
    7-Hydroxycoumarinyl arachidonate
  • HY-116143
    MAGL-IN-12

    		MAGL Metabolic Disease
    SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC50s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .
    MAGL-IN-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: